MID-1|cas:312608-54-1|西域试剂

MID-1,99.91%

产品编号：Bellancom-115461| CAS NO：312608-54-1| 分子式：C₁₂H₁₁N₃O₄S| 分子量：293.30

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-115461	￥1600.00	杭州北京（现货）
Bellancom-115461	￥2500.00	杭州北京（现货）
Bellancom-115461	￥4800.00	杭州北京（现货）
Bellancom-115461	￥7500.00	杭州北京（现货）
Bellancom-115461	￥9900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MID-1

产品介绍

MID-1 是一种 MG53-IRS-1 (Mitsugumin 53-胰岛素受体底物 1) 相互作用的抑制剂。 MID-1 破坏了 MG53 与 IRS-1 的分子缔合，并消除了 MG53 诱导的 IRS-1 泛素化和骨骼肌降解，从而导致 IRS-1 表达水平升高，胰岛素信号传导和葡萄糖摄取增加。

生物活性

MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake.

体外研究

MID-1 (5 μM; 24 h) increases the IRS-1 expression level in skeletal muscle by disrupting the MG53-IRS-1 interaction.
MID-1 (10 μM; 12 h) reduces the luciferase activity in HEK 293 cell line expressing NLUC-IRS-1 and CLUC-C14A.
MID-1 (1-20 μM; 12 h) disrupts the MG53-IRS-1 interaction but not MG53-FAK interaction in HEK 293 cells.
MID-1 (0.1-10 μM; 4-24 h) abolishes MG53-induced IRS-1 ubiquitination and degradation in HEK 293 cells.
MID-1 (5-10 μM; 24 h) increases insulin signaling and insulin-elicited glucose uptake in C2C12 myotubes.
MID-1 (5-10 μM; 24 h) enhances skeletal myogenesis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	C2C12 myotubes
Concentration:	5 μM
Incubation Time:	24 h
Result:	Increased the IRS-1 protein level.

体内研究
(In Vivo)

MID-1 does not have good pharmacokinetics in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

MID-1 does not have good pharmacokinetics in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

MID-1 does not have good pharmacokinetics in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 31.25 mg/mL (106.55 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4095 mL	17.0474 mL	34.0948 mL
5 mM	0.6819 mL	3.4095 mL	6.8190 mL
10 mM	0.3409 mL	1.7047 mL	3.4095 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.08 mg/mL (7.09 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (7.09 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液